In vivo antitumor efficacy of cRGD-PSH-NP/S showed that the tumor inhibition rate of cRGD-PSH-NP/S was 74.71% (Figure 7(B,C)), and the level of survivin in tumors treated with cRGD-PSH-NP/S was significantly lower than that treated with cRGD-NP/S (Figure 7(D)). The gene discussed is BIRC5; the disease is neoplasm.